Drug Trial Radar · NCT07863024
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Mar 10, 2031
Study completion Mar 10, 2031
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body). The study is focused on advanced cancers that have more of a protein called mesenchymal epithelial transition factor (MET) on the surface of their cells than usual. The study drug works by binding to MET on tumor cells and delivering chemotherapy directly into those cells. This may stop growth of the cancer cells and kill only the cancer cells and not the other normal tissues in your body. However, some of the chemotherapy may still affect the normal cells and side effects can still occur. The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body reacts to the study drug, in a way that may cause the study drug to not work as well * What is the best dose of the study drug for treating previously treated, advanced solid tumors
Conditions
- Advanced Solid Tumors
Interventions
REGN13089-M404-M2980Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicities (DLTs)Time frame: Up to 21 days
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to approximately 5 years
- Occurrence of Serious Adverse Events (SAEs)Time frame: Up to approximately 5 years
- Occurrence of adverse event of special interests (AESIs)Time frame: Up to approximately 5 years
- Objective response (OR) (investigator assessed) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1Time frame: Up to approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Carolina BioOncology Institute
Huntersville, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.